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In this report, we summarize the development of a
new endograft system designed to improve on some of the
limitations of the available products. We review the prod-
uct characteristics and early clinical results in Europe and
the United States.
METHODS
Description of the endograft. The modular Ariba
(Teramed, Maple Grove, Minn) Bifurcated Endovascular
System (ABES) consists of a number of stent-graft com-
ponents (Fig 1) and delivery systems built on a single plat-
form (Fig 2). Each stent-graft is constructed of nitinol
stents sutured within a seamless woven polyester bifur-
cated graft. Multiple polyester point and blanket sutures
are used within the aortic and iliac grafts to attach the fab-
ric and stent elements of the device to one another. The
stents are laser cut from seamless nitinol hypotubing and
heat-treated to achieve proper thermal material properties.
Additional electropolishing and other processes create a
rounded, defect-free part that is fatigue resistant and pro-
vides a strong protective barrier to the corrosive in vivo
environment.
The bifurcated aortic trunk is constructed of three
types of nitinol stents: (1) transrenal aortic, (2) midgraft
aortic, and (3) Z-iliac support stents. The transrenal aor-
tic attachment stent has broad open spaces that permit
endograft fixation to the healthy suprarenal aortic segment
while preserving renal artery perfusion. Six to eight fixa-
tion barbs (depending on device diameter) angled caudad
are located on the base of the transrenal attachment device
at the proximal end of the graft fabric to penetrate the aor-
tic wall below the renal arteries and firmly anchor the
endograft into position. The midstent in the main body of
the graft tapers distally to form the bifurcation. Below the
The introduction of endografts for the treatment of
abdominal aortic aneurysms by Volodos1 and Parodi2 in
1991 stimulated the development of a number of products
designed to exclude the lumen of the aneurysm from the
circulation.3-8 This technique of inserting an intraluminal
graft via the femoral arteries is expected to result in throm-
bosis of the sac of the aneurysm and prevention of contin-
ued expansion and rupture. Studies have demonstrated
that the morbidity associated with the placement of endo-
grafts is lower and less severe than that observed with tra-
ditional open aortic surgery. As a result, patients are
discharged from the hospital earlier and recover more
quickly.9-13
Although a number of innovative products have been
introduced, several challenges have emerged. These
include technical issues related to the size of the iliac
artery and arterial calcification and tortuosity14; mechani-
cal problems such as graft wear and stent fractures8;
pathology of the aortic neck such as angulation,14 short
overall length, intraluminal thrombus,15 and expansion;
the presence of aortic and common iliac aneurysms
encroaching on the iliac bifurcation16; and the need to
provide a full variety of products to account for the broad
variations in aortoiliac pathology.
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Twenty-nine patients underwent placement of the Teramed Ariba Endovascular Graft System (Maple Grove, Minn) as
part of a European Feasibility study (14 patients) and a US phase I trial (15 patients). Salient features of this modu-
lar endograft system include a crimped seamless polyester bifurcation graft supplied in three diameters and three iliac
limb lengths, three types of nitinol stents including a suprarenal stent with aortic barbs, a flexible delivery system capa-
ble of controlled incremental sheath retraction, a flexible tapered lead balloon, and a telescoping technique for adjust-
ing the length of graft coverage during surgery over a range of 3 cm. Twenty-eight of the 29 patients met the primary
objective of this evaluation, which was to confirm the safety of the system, defined as the absence of major device-
related adverse events and type I, III, or IV endoleaks within 1 month of implantation. Three major adverse events
occurred within 1 month of discharge: renal failure, which was related to deployment of the device close to the renal
arteries; pulmonary edema, which was related to the procedure but not the device; and peripheral ischemia, which was
related to the patient’s pre-existing condition. Seven patients had type II endoleaks noted by means of computed
tomography scanning at 1 month; the endoleaks were identified by means of angiography and classified at the time of
surgery. There were no deaths, aneurysm ruptures, stent-graft migrations, stent fractures, graft ruptures, graft throm-
boses, or surgical conversions at 1 month. This early clinical experience indicates that the Ariba Bifurcated
Endovascular System can be safely implanted. (J Vasc Surg 2002;35:114-9.)
3-cm body of the graft are two equal-length 5-cm stumps,
into which iliac leg prostheses are inserted and perma-
nently fixed. Each pant leg has a diameter of either 11 mm
or 13 mm, depending on the diameter of the aortic graft.
Along the length of each stump, the prosthetic graft has
circumferential crimps or fabric hinges that form five dis-
crete pockets for fixation of the short sinusoidal nitinol
“Z” stents. This alternating stent-crimp configuration
allows controlled flexibility without kinking and allows the
legs to absorb cyclic motion in the unstented areas. The
aortic grafts are manufactured in three sizes, small (26
mm), medium (30 mm), and large (34 mm), allowing for
significant size overlap and permitting their use in aortic
necks ranging from 18 to 30 mm in diameter. The broad
overlap in sizing of the ABES device reduces the need for
highly precise aortic diameter measurements.
The iliac limbs are constructed of a seamless flared tube
widening to 16 mm or 22 mm over the distal 2 cm. These
limbs are designed to accommodate iliac diameters from 8
to 20 mm. The iliac limb is designed to overlap within the
stump legs of the aortic prosthesis a minimum of 2 cm and
a maximum of 5 cm. This integrated telescoping system
allows in situ iliac graft length adjustments in a 3.0-cm
range. The iliac graft limbs are supplied in three lengths:
10, 12, and 14 cm. Thus, the implanted system will cover
an aortoiliac length from 130 to 200 mm. The narrow iliac
limb body above the bell-bottom graft terminus allows full
expansion through even small distal aortic bifurcations
without residual graft stenosis from compression.
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An aortic extender prosthesis is also available for min-
imal cephalad aortic graft extension. It is fabricated from a
simple polyester tube graft with two supporting diamond-
shaped nitinol stents. The woven polyester tube graft is 3
cm long and is available in three diameters. The polyester
prosthetic material is double thickness on the outside of
the stent in an attempt to reduce the consequences of
micro motion between the fabric and stent of the extender
and primary aortic prosthesis. An iliac bifurcation device
(“Tributary”), designed to treat iliac aneurysms that
extend to the origins of the external and internal arteries,
has been developed and will be the subject of a future pub-
lication. These devices have been tested both in bench top
and animal models; these data are being prepared for sep-
arate reporting.
Description of the delivery system. Each of these
graft prostheses is preloaded in a delivery catheter system,
which is based on a common platform. The delivery
catheters track over 0.035-in guidewires, are highly flexi-
ble, and allow saline to be pressurized within the delivery
sheath to vary the stiffness of the catheter system. A
tapered balloon creates an atraumatic tip for the delivery
system during system insertion. A circular screw-based
handle allows controlled and deliberate retraction of the
outer sheath at 1-mm increments, which exposes the pre-
chilled shape-memory nitinol metal stent to body temper-
ature, triggering expansion.
An ipsilateral delivery catheter, 20F in outer diameter,
contains both the aortic trunk prosthesis and an ipsilateral
iliac limb in tandem fashion. After the aortic graft has been
deployed and the position of the internal iliac artery has
been identified, the delivery catheter is advanced into the
ipsilateral iliac stump, and the iliac limb is deployed, allow-
ing a length variation as much as 3 cm. The contralateral
catheter (17F outer diameter) and the aortic graft exten-
Fig 1. The Ariba Bifurcated Endovascular System (ABES)
includes an aortic body, iliac limbs, iliac and aortic extenders, and
an iliac bifurcation device.
Fig 2. The ipsilateral delivery system, including the ports for the
guidewire, tapered balloon tip (lower inset), and saline infusion; 
the circular deployment wheel; and the flexible sheath containing
the bifurcation and ipsilateral iliac stent grafts in tandem (upper
inset).
sion catheter (23F outer diameter) are similarly designed
for precise, controlled deployment.
Clinical feasibility study. Twenty-nine patients
underwent placement of the ABES as part of a European
Feasibility study (14 patients) and a US Phase I trial (15
patients). The primary objective of this evaluation was to
confirm the safety of the system, defined as the absence of
major device-related adverse events and type I, III, or IV
endoleaks within 1 month of implantation. Clinical suc-
cess for the ABES was defined as graft patency, exclusion
of the aneurysm (absence of proximal or distal attachment
system leaks, fabric holes or junction leaks, or rupture),
and absence of device-related major adverse events within
1 month of implantation. Technical success was deter-
mined on the basis of intent to treat and included all
patients enrolled in the study. Patients were examined to
determine whether each component of the ABES could be
introduced and deployed in the absence of surgical con-
version, intraoperative mortality, type I or type III
endoleaks, or graft limb obstruction.
Patients with unruptured aortic aneurysms who were
also candidates for elective surgical repair were considered
for enrollment. Study patients were examined for their
medical history, disease process, and anatomic suitability
for the study. Only those patients meeting these inclu-
sion/exclusion criteria were enrolled in the study: 21 years
of age or older; not currently enrolled and not anticipated
to enter into a research study for 12 months; man or infer-
tile woman (ie, with a condition that prevents pregnancy,
such as hysterectomy, tubal ligation, or post-menopausal);
provided written informed consent; surgical candidate;
aneurysm 4.5 cm in diameter or larger, or saccular
aneurysm larger than 3.0 cm, or aneurysm more than
twice the normal aortic diameter, or rapidly growing
aneurysm (0.5 cm in 6 months), or symptomatic or tender
aneurysm; aneurysm starting 10 mm or more below the
most distal renal artery; diameter of proximal aortic
attachment site between 22 and 26 mm; device coverage
length of 13 to 20 cm extending from the lowest renal
ostium to the distal anchoring site in the common iliac
artery; diameter of common iliac artery between 8 and 14
mm (USA) or between 8 and 20 mm (Europe); iliac artery
having approximately 10 mm of normal vessel located at
the distal attachment site; and iliac artery with adequate
peripheral access to accommodate a 20F delivery system.
Exclusion criteria included a weight of 350 lb (159
kg) or more; mycotic or ruptured aneurysm; life
expectancy less than 1 year; myocardial infarction or cere-
bral vascular accident; documented history of drug or
alcohol abuse within past 6 months; required occlusion or
re-implantation of significant mesenteric or renal arteries;
planned concomitant surgical procedure or earlier major
surgery within 30 days; severe allergy to contrast; a condi-
tion requiring chronic anticoagulation; peripheral white
blood cell count less than 1500/mm3 or platelet counts
less than 50,000/mm3; renal insufficiency (creatinine level
higher than 2.5 mg/dL) without dialysis; mechanical
heart valves or organ transplants requiring immunosup-
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pression therapy; vascular prostheses in aortoiliac arteries
(ie, in area of procedure); degenerative connective tissue
disease (eg, Marfan’s or Ehlers Danlos Syndrome); history
of atheromatous embolization; chronic dissection; intralu-
minal filling defect in aortic neck above the lowest renal
artery; thrombus in neck area covering more than 50% of
the endoluminal surface; and iliac anatomy that would
require occlusion of both internal iliac arteries.
Twenty-nine patients underwent implantation of an
ABES between Dec 6, 1999, and Aug 23, 2000, at one of
four clinical centers: Mount Sinai School of Medicine (10
patients), Carle Clinic (3 patients), Newark Beth Israel
Medical Center (2 patients), and Slovak Institute of
Cardiovascular Diseases (14 patients).
The preoperative evaluation included history, physical
examination, laboratory tests, and high resolution com-
puted tomography (CT) scans with and without contrast
enhancement. All patients returned for a 1-month follow-
up visit. All visits required patient history, physical exami-
nation, abdominal radiographs, and CT scanning.
Imaging studies were evaluated by one of two qualified
core laboratories in support of an unbiased and consistent
evaluation of the status of the ABES, aneurysm sac, blood
flow, and surrounding vasculature during the course of the
study. High-resolution CT scans and angiograms (Fig 3)
obtained before the procedure were used as a means of
determining aneurysm diameter, aortic neck length and
diameter, diameter of the iliac arteries, and the length
from the renal arteries to the landing zone in the common
iliac arteries. At each follow-up evaluation, these parame-
ters were assessed: presence of endoleak(s); obstruction or
narrowing of the prosthesis lumen; and any pathological
changes that may have occurred in the aorta or iliac arter-
ies, aneurysm sac, or prosthesis. Abdominal radiographs
(Fig 4) were obtained after implantation as a means of
assessing stent strut integrity and stent-graft migration.
Major adverse events were characterized as serious con-
ditions that threatened life or limb or resulted in unex-
pected delays in discharge or surgical procedures. These
included myocardial infraction, stroke, heart failure, symp-
tomatic arrhythmia, peripheral ischemia, renal failure, pneu-
monia, bleeding requiring transfusion or surgery, etc.
Minor adverse events were characterized as non-threatening
events that did not delay discharge and were transient, but
added some morbidity not always associated with the pro-
cedure. These included urinary tract infection, hematoma
not requiring surgery, atalectasis, minor arrhythmia, etc.
RESULTS
Twenty-seven of the 29 patients (93%) were men; the
average age was 69.8 ± 8.5 years (USA, 73.3 years;
Europe, 66.1 years). The demographics were typical of
patients with abdominal aortic aneurysms (coronary artery
disease, 69%; hypertension, 79.3%; diabetes mellitus,
20.7%; creatinine level < 1.5, 93.1%; creatinine level
between 1.5 and 2.5, 6.9%; smoking 51.8%).
The average maximum aneurysm diameter was 53.3 ±
9.1 mm (range, 45-80 mm). The aortic neck lengths
ranged from 10 to 44 mm (mean, 25.8 ± 10.2 mm).
Aortic neck diameters ranged from 22 to 26 mm (mean,
23.8 ± 1.6 mm). The lowest renal artery to internal iliac
length ranged from 130 to 200 mm (mean, 167 mm
right, 171 mm left). Common iliac diameters ranged from
10 to 30 mm (mean, 13.4 mm right, 13.3 mm left).
The 30-mm trunk diameter was used exclusively in
this trial, resulting in oversizing of 4 to 8 mm (mean, 6.2
mm). The length of the iliac prostheses ranged from 10 to
14 cm. Both the smaller 11- to 16-mm prosthesis diame-
ter and the larger 13- to 22-mm (Europe, 4 patients) pros-
thesis diameter were used. Iliac artery oversizing ranged
from 2 to 9 mm (mean, 3.7 mm). In addition, the
European site used 1 aortic extension.
With plain radiographs and CT scans, the core labora-
tories reviewed these prosthesis parameters: prosthesis
migration, stent integrity, graft patency, graft rupture, and
presence of endoleak. Prosthesis migration was defined as
more than 5 mm of displacement on the radiograph. With
bony landmarks as reference points, the core laboratories
found no evidence of migration, stent fractures, graft rup-
ture, or graft occlusion.
Adverse events. An independent physician reviewer
adjudicated adverse events to ensure consistent reporting.
There were no deaths, aneurysm ruptures, stent-graft
migrations, stent fractures, graft ruptures or surgical con-
versions. There were three major adverse events reported
within 1 month of the procedure.
After aneurysm repair, postoperative oliguria and an
increase in the blood urea nitrogen and serum creatinine
levels developed in an 80-year-old man with a 6-cm
abdominal aortic aneurysm and bilateral renal artery
stenosis. The graft had been deployed just below the ori-
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fices of the renal arteries, but contrast flowed into the
renal vessels. On the third postoperative day, a duplex
ultrasound scan was performed, by means of which poor
flow into the renal arteries was demonstrated. Subtotal
occlusion of the renal arteries was demonstrated by means
of an angiogram. An attempt was made to recanalize the
diseased renal arteries; however, this was not successful. A
right hepatorenal bypass grafting procedure was per-
formed. The creatinine levels remained elevated at the 1-
month evaluation, and dialysis was initiated. The
endograft remained patent, and the aneurysm excluded.
After completing the implant procedure, a second
patient experienced congestive heart failure, which
responded to medical measures. The condition resolved
without sequelae. A third patient had peripheral vascular
disease of both lower extremities before implantation of
the stent-graft. The physician performed a femoral
popliteal bypass grafting procedure in the left leg as an
adjunctive procedure to correct lower-extremity periph-
eral vascular ischemia caused by a chronic superficial
femoral artery occlusion. The endograft was patent. The
adverse event in the first patient was related to the deploy-
ment technique. The episode of pulmonary edema was
related to the procedure; the ischemic disease was related
to the patient’s pre-existing medical condition.
Five minor adverse events occurred before discharge.
None was life or limb threatening. They included one
groin hematoma that did not require surgery, two urinary
tract infections, one peripheral ischemic event that did not
require intervention at 1, 3, and 6 months, and one tran-
sient episode of renal insufficiency that was absent at 1 and
3 months.
Endoleaks. There were no type I, III, or IV
endoleaks either at surgery or at the 1-month follow-up.
Fig 3. Intraoperative angiograms before and after ABES implan-
tation in a patient with favorable anatomy.
Fig 4. Plain radiographs of the ABES.
Seven of 29 patients (24%) had type II endoleaks, on the
basis of core laboratory review of the images obtained
within 1 month of implantation; four of these patients
were from Europe, and three were from the United States.
Two endoleaks originated at the lumbar arteries, and five
originated at the inferior mesenteric artery (IMA).
End points. A primary end point of this feasibility
study was the safety of the device, defined as the absence
of major device-related adverse events and type I, III, or
IV endoleaks within 1 month of implantation. Of the 29
patients who underwent implantation with the ABES, 28
patients (97%) reached the primary end point. Renal insuf-
ficiency developed in one patient, probably as a result of a
technical error in deployment. Clinical success was defined
as graft patency, exclusion of the aneurysm (absence of
type I, III, or IV leaks or aneurysm rupture at the 1-
month follow-up evaluation), and absence of device-
related major adverse events at the 1-month follow-up
evaluation. All 29 patients (100%) had an excluded
aneurysm and a patent stent-graft; no patients had a type
I, III, or IV endoleak, and 1 patient (3.4%) had a major
adverse event (renal insufficiency), which was probably
related to the procedure.
Technical success was determined on the basis of
intent to treat and included all patients enrolled in the
study. Patients were examined to determine whether each
component of the ABES could be introduced and
deployed in the absence of surgical conversion, intraoper-
ative mortality, type I or III endoleaks, or graft limb
obstruction.
During one implantation, the operator did not retract
the contralateral sheath properly, which resulted in the
graft not exiting the delivery system. The system was
removed, and a second system was inserted and deployed
with the correct technique. Thus, technical success was
achieved in 28 of 29 patients (97%).
DISCUSSION
It has been clearly shown that endovascular repair of
abdominal aortic aneurysms shortens hospitalization and
recovery time and lowers the incidence and magnitude of
morbid events after surgery.9-13 However, certain
anatomic conditions, such as tortuosity, calcification, and
stenosis continue to challenge successful access through
the iliac arteries. Additionally, some available products are
not designed to treat aortic aneurysms with short or tor-
tuous aortic necks, large-diameter aortic necks and iliac
arteries, and associated iliac aneurysms. Furthermore,
issues such as stent fatigue and fabric erosions are con-
cerns.17-19 Finally, the design of some endografts will
demand a significant investment in product inventory
because of the number of different sizes needed to treat
the patient population.
The ABES has been developed to ameliorate some of
these difficulties. The delivery system, with its tapered tip,
flexibility, and 20F diameter, allowed passage through tor-
tuous, calcified, and narrow iliac vessels in some patients in
this study. The circular deployment wheel allowed minute
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incremental retraction of the sheath, so that the graft could
be placed accurately within millimeters of the target artery
in more than 90% of patients. Nevertheless, technical
errors can occur when deployment is too close to the renal
arteries. The suprarenal fixation device combines radial
force of the nitinol stent above the renal arteries and hook
fixation in the aorta just below the renal arteries to maxi-
mize fixation in the most proximal infrarenal aorta. This
allowed fixation of the graft in a few patients with very
short aortic necks; however, the prosthetic fabric has to
provide a seal to prevent a proximal endoleak. A longer fol-
low-up period will be necessary to determine whether this
goal is reached. Data from this study and others20-22 indi-
cate that when properly applied, suprarenal fixation is not
associated with thrombus formation or deterioration in
renal function in most cases. Early results in a few patients
with angulated necks indicate that this proximal suprarenal
stent, when combined with the flexibility of the upper por-
tion of the body of the graft, provided good contact with
the aortic wall and established a good seal at 1 month.
The feasibility study was carried out with a single 30-
mm diameter graft body, and 16- and 22-mm diameter
iliac limbs that were 10, 12, or 14 cm in length. Two other
aortic bifurcation graft diameters, 26 and 34 mm, are avail-
able but were not used in this study. This combination of
grafts will be useful for aortic neck diameters from 18 to 30
mm, iliac artery diameters from 8 to 20 mm, and graft
lengths from 130 to 200 mm. Oversizing of as much as 8
mm in the aortic prosthesis and 9 mm in the iliac prosthe-
sis of the ABES did not lead to thrombosis or rupture.
One important challenge is the careful selection of an
endograft of appropriate length to effectively exclude the
involved segments of the aorta and iliac arteries. Choosing
the precise length for the iliac limbs of an endograft may
be confounded by unpredictable angulation and by inher-
ent inaccuracies associated with radiological measuring
techniques. In addition, it is often difficult to predict the
course an endograft will follow in the aneurysm sac before
deployment, further complicating precise length determi-
nations.
The ABES allowed appropriate sizing within the
patient during the procedure (“in situ sizing”) to exclude
the common iliac arteries and accurately preserve the
internal iliac arteries. The 5-cm stump legs of the main
graft allow the iliac limbs to overlap 2 to 5 cm. By choos-
ing an iliac graft approximating the required length and
performing intraoperative angiography, one can extend
the distal edge of graft prosthesis to within millimeters of
the origins of the internal iliac arteries.
The primary objective of this feasibility study was to
confirm the safety of the ABES, which was defined as the
absence of major device-related adverse events and type I,
III, or IV endoleaks within 1 month of implantation.
There were no deaths, conversions to open aortic surgery,
stent-graft migrations, stent fractures, graft ruptures, or
aneurysm ruptures. The primary objective was achieved in
28 of 29 patients (97%; 14/14 in Europe and 14/15 in
the United States). Renal insufficiency developed in one
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patient after implantation, a complication that may have
been related to placing the device too close to the renal
orifices. Two other major adverse events, congestive fail-
ure and worsening of chronic arterial insufficiency, were
not related to the device, although they may have been
related to the procedure, the patients’ pre-existing medical
conditions, or both. There were five minor adverse events.
There were no type I or III endoleaks at the time of
graft implantation or at the 1-month follow-up evaluation,
and there were seven type II endoleaks proven by means
of angiography. No additional medical intervention has
been necessary for any of these patients.
In summary, initial clinical experience indicates that
the ABES can be safely implanted.
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